Vertical Pharmaceuticals, Inc. today announced that Vertical and Nautilus Neurosciences have entered into a co-promotion agreement for Lorzone™ (chlorzoxazone tablets, USP), a safe, effective, and fast-acting muscle relaxant that is not associated with significant sedation or drowsiness.
“We are extremely excited about this co-promote opportunity with Nautilus as they bring a highly regarded and professional sales force to our existing commercialization efforts in support of Lorzone”
Under the terms of the agreement, Vertical and Nautilus will co-promote Lorzone™ with a combined nationwide sales force of 115 sales representatives in the US market. Nautilus will focus product promotion efforts on their current target list specializing in the neurology field.
"We are extremely excited about this co-promote opportunity with Nautilus as they bring a highly regarded and professional sales force to our existing commercialization efforts in support of Lorzone," said Greg Voyles, Vertical's Chief Operating Officer. "With the addition of the Nautilus sales force we can expand our promotional reach into a new marketplace and give prescribers an opportunity to offer their patients an important option in this therapeutic category."
"We look forward to working with our partners at Vertical to launch Lorzone to our customers," said William Maichle, Chief Executive Officer, Nautilus Neurosciences. "We are committed to providing valuable, life-changing therapies to our patients and healthcare providers and feel Lorzone is consistent with the Nautilus mission."
Study shows how a single defective BRCA1 gene accelerates cancer development